Seasonal Influenza Vaccine Market in Asia-Pacific to 2018
DUBLIN, July 10, 2013 /PRNewswire/ –
Research and Markets (http://www.researchandmarkets.com/research/gqwvmq/seasonal)
has announced the addition of the “Seasonal Influenza Vaccine Market in Asia-Pacific to
2018 – Positive Impact of Government Support Offset by Limited Production Capacity, High
Investment and Strict Regulations as Barriers to New Entrants”
[http://www.researchandmarkets.com/research/gqwvmq/seasonal ] report to their offering.
GBI Research, the leading business intelligence provider has released its latest
research Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 – Positive Impact of
Government Support Offset by Limited Production Capacity, High Investment and Strict
Regulations as Barriers to New Entrants which essentially provides insights into the
seasonal influenza vaccine sales forecasts for the Asia-Pacific Region until 2018.
The report also delves deep into vaccination patterns for seasonal influenza in the
Asia-Pacific Region. Further, the geographical distribution of seasonal influenza vaccines
across Japan, Australia, New Zealand, China, Taiwan, Philippines, Hong Kong, Malaysia,
India and Singapore are also provided in the report. The report offers a clear view of the
regulatory landscape in the Asia-Pacific countries. The report also reveals the seasonal
influenza vaccine R&D pipeline and offers profiles of promising vaccines. The report
explores the competitive landscape including profiles for top companies. Finally, the key
trend analysis on mergers and acquisitions, and licensing agreements involving seasonal
influenza vaccines is also presented.
Treatment of seasonal influenza is dominated by two categories of treatment options,
vaccines and antiviral therapies. In the recent years it was observed that demand for
seasonal influenza vaccines have increased due to changed perception of patient
population. The patient population is of the opinion that preventive healthcare is better
compared to curative healthcare; this led to increased demand of vaccines in Asia-Pacific
region. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine
Major drivers in the market is increasing awareness, increasing vaccination coverage
in the APAC countries and rising government support for immunization against seasonal
influenza. Major restraints of the market are variable demand and limited production
capacity. Traditional egg based manufacturing of seasonal influenza vaccines is being
replaced with cell culture vaccines. Cell culture based production of vaccines is expected
to reduce the problems associated with the production and use of seasonal influenza
vaccines which will further increase the vaccination coverage in the APAC region.
GBI Research Analysis shows that the seasonal influenza vaccine market in the APAC
Region is a fast growing market. This is due to increased vaccination coverage against
seasonal influenza in the region. GBI Research forecasts the market to grow at double
digit Compounded Annual Growth Rate (CAGR) of 9% during the period 2011-2018 from $1,015m
in 2011 to $1,879m by 2018. This growth is driven by factors such as increasing awareness
on influenza caused by threat of pandemic influenza, increasing vaccination coverage
because of the governments’ support, growing population in the APAC region and entry of
novel vaccines and production technologies.
GBI Research finds that the Philippines’ seasonal influenza vaccine market is the most
attractive in the seasonal influenza vaccine
[http://www.researchandmarkets.com/research/gqwvmq/seasonal ] market for Asia-Pacific
region both in terms of value and growth rate. Other attractive markets in terms of growth
rate are Malaysia’s and Singapore’s seasonal influenza vaccine markets. Australia’s
seasonal influenza vaccine market is also a large sized attractive market forecast to grow
at a healthy growth rate during the period 2011-2018. In-depth analysis of the report is
based on propriety databases, primary and secondary research and in house analysis by the
GBI Research team of experts.
GBI Research analysis shows that the R&D pipeline for the seasonal influenza vaccines
is moderately strong with approximately 50% of the pipeline in the Phase II and Phase III.
The major vaccine manufacturers are focused upon acquiring new technologies and
strengthening their presence in the market by collaborating with or acquiring small and
medium sized biotech companies that have strong vaccine candidates in their pipeline. The
R&D activity also indicates development of new technologies and novel vaccines that can
revolutionize the market in near future.
– The report analyses vaccination patterns, market characterization, regulatory
landscape, pipeline analysis, competitive landscape and key M&A trends in the seasonal
influenza vaccine market in the APAC region.
– Data and analysis on the seasonal influenza vaccine market in the Asia-Pacific
Region including Japan, Australia, New Zealand, China, Taiwan, Philippines, Malaysia, Hong
Kong, India and Singapore.
– Market forecasts for the seasonal influenza vaccines from 2011 to 2018
– Market Data on geographical landscape including country wise vaccination coverage,
public and private contribution on total doses, price of vaccine, market size and market
– Key drivers and restraints that have created significant impact on the market.
– Regulatory landscape including the pharmaceutical product approval process and
overview of regulatory authorities in the countries in Asia-Pacific region
– Competitive landscape of the seasonal influenza vaccine market in Asia-Pacific
region including top companies profiles. The key companies studied in this report are
Sanofi Pasteur, Abbott Laboratories, GlaxoSmithKline Biologicals, Novartis Vaccines, CSL
Biotherapies and Crucell.
– Key M&A activities, Licensing Agreements, that have taken place between 2007 and
2012 in the seasonal influenza vaccine market.
- Sanofi Pasteur - GlaxoSmithKline Biologicals - Abbott Laboratories (Solvay Pharmaceuticals) - CSL Biotherapies - Novartis Vaccines - Crucell N.V. (Berna Biotech)
For more information visit
About Research and Markets
Research and Markets is the world’s leading source for international market research
reports and market data. We provide you with the latest data on international and regional
markets, key industries, the top companies, new products and the latest trends.
Research and Markets Laura Wood, Senior Manager. firstname.lastname@example.org U.S. Fax: +1-646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Healthcare and Medical Devices [http://www.researchandmarkets.com/categories.asp?cat_id=12&campaign_id=gqwvmq ]
SOURCE Research and Markets